Seneca Biopharma (SNCA) Short Interest Ratio & Short Volume

Short interest is the volume of Seneca Biopharma shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 1,720,000 shares of SNCA short. 9.95% of Seneca Biopharma's shares are currently sold short. Learn More on Seneca Biopharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.95% of Seneca Biopharma's floating shares are currently sold short.

Seneca Biopharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,720,000 shares, an increase of 22.0% from the previous total of 1,410,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Seneca Biopharma currently has issued a total of 17,296,000 shares. Some of Seneca Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Seneca Biopharma currently has a public float of 17,280,000 shares.

9.95% of Seneca Biopharma's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Seneca Biopharma: bluebird bio, Inc. (27.21%), Outlook Therapeutics, Inc. (6.16%), Vigil Neuroscience, Inc. (7.06%), BioAtla, Inc. (11.62%), aTyr Pharma, Inc. (0.64%), Sangamo Therapeutics, Inc. (5.50%), AlloVir, Inc. (5.48%), Curis, Inc. (0.85%), Atara Biotherapeutics, Inc. (9.41%), Cardiol Therapeutics Inc. (0.53%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Analog Devices, Inc. ($5.85 billion), Aon plc ($5.61 billion), Charter Communications, Inc. ($5.44 billion), Snap Inc. ($3.49 billion), Airbnb, Inc. ($3.35 billion), Peloton Interactive, Inc. ($2.53 billion), Expedia Group, Inc. ($2.39 billion), The Kroger Co. ($2.26 billion), Nuance Communications, Inc. ($2.18 billion), and Palo Alto Networks, Inc. ($1.84 billion). View all of the most shorted stocks.

Short selling SNCA is an investing strategy that aims to generate trading profit from Seneca Biopharma as its price is falling. SNCA shares are trading up $0.43 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Seneca Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SNCA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SNCA, twice per month. The most recent reporting period available is April, 15 2021.